Queensland biotechnology company Vaxxas has raised $25 million in a Series B funding round, which will be used to advance clinical trials of its innovative technology that could one day lead to the end of the vaccine syringe.
Workforce management startup Ento closes $5m series B
CSIRO VC fund Main Sequence backs $3 million series A for communications compliance startup
Here are the 7 incredible startups in the latest Remarkable program helping people with disabilities
Billionaire Alex Waislitz and regional media tsar Antony Catalano chip $6 million into AI-based proptech
Daily startup news and insights, delivered to your inbox.
